
Product Data Sheet

Product Name: MLANA Human
Cat. No.: GP23929
Batch No.: 1

Product Data

Purity	>98%	Source	Escherichia Coli.
Physical Appearance	solid	Shipping Condition	Shipped with Ice Packs.
Synonyms	MART-1; MART1; Melanoma antigen recognized by T-cells 1; Antigen LB39-AA; Antigen SK29-AA; Protein Melan-A; MLANA.		
Amino Acid Sequence	MGSSHHHHHH SGLVPRGSH MGSCRRRNGY RALMDKSLHV GTQCALTRRC PQEGFDHRDS KVSLQEKNCE PVVPNAPPAY EKLSAEQSPP PYSP.		
Formulation	The MLANA solution (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 20% glycerol and 1mM DTT.		

Introduction

Melan-A (MLANA), is engaged in melanosome biogenesis by ensuring the stability of GPR143. MLANA takes part in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is essential to the formation of stage II melanosomes.

Stability

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

Background

MLANA Human Recombinant produced in E. coli is a single polypeptide chain containing 94 amino acids (48-118) and having a molecular mass of 10.4kDa. MLANA is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA